Risk Factors Update Summary
- Anticipate increased expenses for research, development, and commercialization activities, with cash holdings decreasing from $267 million to $221 million.
- Strategic realignment to focus on Abecma development may cause disruptions, with a reduction in workforce by approximately 40%.
- Regulatory delays or rejections may impact the commercial prospects of product candidates, with potential delays in clinical trials.
- Uncertainty in completing clinical trials may delay product revenues and harm business prospects.
- Potential delays in clinical trials could lead to increased costs and hinder product sales and revenue recognition.
- Cybersecurity incidents pose a significant risk, with potential disruptions to operations and harm to the company's reputation.
- Failure to raise additional capital may impact operations and hinder the development and commercialization of future products.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1860782&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.